Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Groupon Finalizes $260 Million Deal for Ticket Monster, LivingSocial’s Korean Business

The deal should give Groupon’s discount product business a boost in Asia.

Juan Camilo Bernal / Shutterstock
Jason Del Rey
Jason Del Rey has been a business journalist for 15 years and has covered Amazon, Walmart, and the e-commerce industry for the last decade. He was a senior correspondent at Vox.

Groupon announced Thursday that it had closed its acquisition of Ticket Monster, the Korean deals company owned by LivingSocial. Groupon said it paid $260 million in total for Ticket Monster — $160 million in stock and $100 million in cash.

A look at Ticket Monster’s financials suggest that Groupon didn’t acquire it for the business it is now, but for what it thinks it can be down the line.

The company, which launched in 2010 and was acquired by LivingSocial in 2011, registered an operating loss of nearly $39 million on $78.5 million in revenue in the first nine months of 2013, Groupon said. That said, nearly all of the loss can be attributed to stock-based compensation and other non-cash expenses.

“Excluding these non-cash items, the company was about break-even on an adjusted EBITDA basis,” Groupon said in a filing. “This is quite an accomplishment for a company that is not yet four years old.”

LivingSocial’s current model also comes with thinner margins than Groupon’s overall business. While Groupon built its foundation on discount offerings to local service businesses, Ticket Monster has relied more on the discounted sales of physical products. About 65 percent of its offerings are products, another 20 percent to 25 percent are local-business deals, and the remainder are travel deals, the filing said. For comparison’s sake, Groupon’s Goods product business accounted for about 40 percent of its total revenue in the third quarter.

Since product sales typically generate thinner margins than local deals, Ticket Monster’s “take rate” — or the cut of total billings that it keeps — is significantly lower than Groupon’s overall. Groupon said it will work with the company to strengthen those rates.

Ticket Monster had about 1,000 employees at the time of acquisition, though it’s not clear how many Groupon will hold onto.

LivingSocial will be able to sell the Groupon shares it receives in the deal, with some restrictions.

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh